ArticleBMJ open diabetes research & care2026
Serum soluble ASGR1 concentration is elevated in patients with metabolic dysfunction-associated steatotic liver disease and is associated with adiponectin.
Article in BMJ open diabetes research & care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCurrent studies have shown that the asialoglycoprotein receptor 1 (ASGR1) is involved in glycolipid metabolism and is associated with systemic insulin resistance. This study aims to explore the correlation between serum soluble ASGR1 (sASGR1) levels and metabolic dysfunction-associated steatotic liver disease (MASLD) by assessing the relationship between sASGR1 concentrations and various biomarker levels.
methodsThe study included 148 patients diagnosed with MASLD from December 2021 to July 2024, and 98 control participants from the general population without MASLD. After collecting baseline clinical characteristics, ELISA kits were used to measure serum levels of sASGR1, fibroblast growth factor 21, and adiponectin.
resultsCompared with the control group, patients with MASLD had higher serum sASGR1 levels (p<0.05). Spearman correlation analysis showed that serum sASGR1 levels were significantly positively correlated with lipid metabolism indicators (triglycerides, total cholesterol, low-density lipoprotein cholesterol), glucose metabolism indicators (fasting plasma glucose, fasting insulin, glycosylated hemoglobin, homeostasis model assessment for insulin resistance), inflammatory markers (tumor necrosis factor α), liver function, and liver fibrosis. indicators (alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase, procollagen type III, hyaluronic acid), and body mass index (p<0.05), and were significantly negatively correlated with high-density lipoprotein cholesterol (p<0.05). Further multiple linear regression analysis showed sASGR1 may be an independent risk factor for the occurrence of MASLD after adjusting for potential confounding factors (OR 2.644, 95% CI 1.138 to 6.143; p<0.05). The receiver operating characteristic curve revealed that the area under the curve for serum sASGR1 in predicting MASLD occurrence was 0.761 (95% CI 0.698 to 0.824), and its predictive performance increased to 0.863 (95% CI 0.813 to 0.913) when combined with AST and ALT.
conclusionsIn this group of patients with MASLD, sASGR1 levels are higher and are associated with the occurrence of MASLD, suggesting that sASGR1 may be an independent risk factor for MASLD. TRIAL REGISTRATION NUMBER: The expression of organokines in serum and its relationship with inflammation, insulin resistance in obese patients, ChiCTR2200059056.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.